This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech

Charter Communications Hopes to Succeed Where Comcast Didn't

Durable Goods orders fell a half percent in April matching estimates.

05/26/15 - 09:51 AM EDT

4 Big Biotech Companies to Sell Now

Biotech stocks are one of the hottest investment areas these days, but not all biotech stocks are smart buys.

05/26/15 - 08:30 AM EDT

5 Investments That Show John Paulson Knows How to Play M&A

5 Investments That Show John Paulson Knows How to Play M&A

John Paulson said in a 2014 interview that he expected high levels of M&A activity to continue "for the foreseeable future." He has invested accordingly, and it is paying off.

05/22/15 - 12:28 PM EDT

Netflix, ZS Pharma Get Price Target Hikes; Gap Is Losing Relevance

Netflix, ZS Pharma Get Price Target Hikes; Gap Is Losing Relevance

In Friday's Analysts' Actions, we highlight higher price targets on Netflix Inc (NFLX) and ZS Pharma (ZSPH), while Gap Inc (GPS) gets hit with some negative notes.

05/22/15 - 10:14 AM EDT

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

05/22/15 - 06:01 AM EDT

IntelliPharmaCeutics Int'l. (IPCI) Stock Spikes on Positive Non-Abusive Oxycontin Development

IntelliPharmaCeutics Int'l. (IPCI) Stock Spikes on Positive Non-Abusive Oxycontin Development

  • Tickers in this article:
  • IPCI

IntelliPharmaCeutics (IPCI) shares are up double digits as the company announced plans to possibly accelerate the development of its abuse-deterrent oxycontin treatment.

05/21/15 - 11:18 AM EDT

IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price

IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price

  • Tickers in this article:
  • ISR

IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy but makes up for it by issuing a lot of promotional press releases.

05/21/15 - 11:36 AM EDT

Johnson & Johnson Plans for 10 New Drugs -- Is It Time to Own the Stock?

Johnson & Johnson Plans for 10 New Drugs -- Is It Time to Own the Stock?

  • Tickers in this article:
  • JNJ

Johnson & Johnson announced plans to file for federal approval of at least 10 potential blockbuster new drugs over the next four years. What does this mean for the stock?

05/20/15 - 02:49 PM EDT

Why Dupont Came Out on Top in Proxy Fight With Nelson Peltz

Why Dupont Came Out on Top in Proxy Fight With Nelson Peltz

  • Tickers in this article:
  • DD

When Nelson Peltz tried to secure a spot on the board of E.I. Du Pont de Nemours and Co. (DD), two major proxy advisory firms sided with him.

05/20/15 - 02:08 PM EDT

Johnson & Johnson Announces it Will File for Ten New Drugs by 2019

Johnson & Johnson Announces it Will File for Ten New Drugs by 2019

  • Tickers in this article:
  • JNJ

Johnson & Johnson (JNJ) announced its Janssen Pharmaceutical segment will file for regulatory approval of at least ten new drugs by 2019.

05/20/15 - 12:27 PM EDT

Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying

Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying

TheStreet's Jim Cramer says Regeneron Pharmaceuticals' shares are headed even higher, and he comments on the huge rally in Sarepta Therapeutics' stock.

05/20/15 - 11:07 AM EDT

VWR, the Lab Equipment Maker, Shows Its Hand in Dealmaking After IPO

VWR, the Lab Equipment Maker, Shows Its Hand in Dealmaking After IPO

  • Tickers in this article:
  • VWR

Lab equipment maker VWR International has hardly been idle since going public last fall. A large player in Europe, the firm has been quite active on the dealmaking front.

05/19/15 - 06:16 PM EDT

Industrials Undervalued, Biotech Boom Not Done Says LPL Financial CIO

Industrials Undervalued, Biotech Boom Not Done Says LPL Financial CIO

The Industrial Select Sector SPDR ETF (XLI) trades cheaply and industrial companies will benefit from the dollar's stabilization, said Burt White, Chief Investment Officer for LPL Financial.

05/19/15 - 05:56 PM EDT

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.

05/19/15 - 04:42 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,072.90 -159.12 -0.87%
S&P 500 2,110.51 -15.55 -0.73%
NASDAQ 5,039.9080 -49.4540 -0.97%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs